IMVT Earnings

Quarterly EPS
$-0.74
Q2 2025
$-0.76
Q3 2025
$-0.64
Q4 2025
$-0.71
Q1 2026
$-0.73
Q2 2026
$-0.61
Q3 2026
$-0.73
Q4 2026
$-0.75
Q1 2027
Latest RevenueN/A
Latest Net Income-153224000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q1 2027-$0.750-153224000-5.6%
Q4 2026-$0.730-147856000-14.1%
Q3 2026-$0.610-110635000+19.7%
Q2 2026-$0.730-126502000+1.4%
Q1 2026-$0.710-120613000-18.3%
Q4 2025-$0.640-106449000-23.1%
Q3 2025-$0.760-111122000-111.1%
Q2 2025-$0.740-109119000-64.4%
Q1 2025-$0.600-87150000
Q4 2024-$0.520-75319000
Q3 2024-$0.360-51418000
Q2 2024-$0.450-58662000
Immunovant (IMVT) — Earnings